Biotheranostics was acquired by Hologic in February 2021, and continues to offer its portfolio of proprietary genomic assays to support personalized disease management in oncology. Visit Hologic.com.
The only genomic test recognized by ASCO® and NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) to help predict benefit of extended endocrine therapy in HR+, early-stage breast cancer. 1,2
The most validated gene expression based assay to help identify the tumor type and subtype for metastatic cancer patients with unknown or unclear diagnoses.